Potential conflict of interest: The antimurine MCP-1 inhibitor, mNOX-E36, was kindly provided by NOXXON Pharma AG. D.E. is an employee of NOXXON Pharma AG (Berlin, Germany).
Liver Failure/Cirrhosis/Portal Hypertension
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+ macrophage infiltration in mice
Article first published online: 30 JAN 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 59, Issue 3, pages 1060–1072, March 2014
How to Cite
Baeck, C., Wei, X., Bartneck, M., Fech, V., Heymann, F., Gassler, N., Hittatiya, K., Eulberg, D., Luedde, T., Trautwein, C. and Tacke, F. (2014), Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+ macrophage infiltration in mice. Hepatology, 59: 1060–1072. doi: 10.1002/hep.26783
This work was supported by the German Research Foundation (DFG Ta434/2-1 and DFG SFB/TRR 57) and by the Interdisciplinary Center for Clinical Research (IZKF), Aachen, Germany.
- Issue published online: 25 FEB 2014
- Article first published online: 30 JAN 2014
- Accepted manuscript online: 8 OCT 2013 02:55PM EST
- Manuscript Accepted: 1 OCT 2013
- Manuscript Received: 5 APR 2013
Options for accessing this content:
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.